The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 11, 2017

Filed:

Mar. 15, 2013
Applicants:

Maiken Nedergaard, Webster, NY (US);

Alexander Stanley Thrane, Oslo, NO;

Vinita Rangroo Thrane, Oslo, NO;

Inventors:

Maiken Nedergaard, Webster, NY (US);

Alexander Stanley Thrane, Oslo, NO;

Vinita Rangroo Thrane, Oslo, NO;

Assignee:

University of Rochester, Rochester, NY (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/18 (2006.01); A61K 31/4152 (2006.01); A61K 31/454 (2006.01); A61K 31/635 (2006.01); A61K 31/192 (2006.01); A61K 31/44 (2006.01); A61K 31/196 (2006.01); A61K 31/4035 (2006.01); A61K 31/341 (2006.01); A61K 31/402 (2006.01); A61K 31/41 (2006.01);
U.S. Cl.
CPC ...
A61K 31/635 (2013.01); A61K 31/18 (2013.01); A61K 31/192 (2013.01); A61K 31/196 (2013.01); A61K 31/341 (2013.01); A61K 31/402 (2013.01); A61K 31/4035 (2013.01); A61K 31/41 (2013.01); A61K 31/4152 (2013.01); A61K 31/44 (2013.01); A61K 31/454 (2013.01);
Abstract

The disclosure relates to a method of treating and/or preventing brain impairment in a subject that has or is susceptible to ammonia neurotoxicity (increased plasma ammonia), by administering a Na-; —K+-2CI- cotransporter isoform 1 ('NKCC1') inhibitor to the selected subject under conditions effective to treat and/or prevent brain impairment. The disclosure further relates to methods of maintaining the fundamental function of astrocytic potassium buffering and inhibiting accumulation of potassium star rounding astrocytes, both of which involve contacting astrocytes with a NKCC 1 inhibitor.


Find Patent Forward Citations

Loading…